Search

Displaying results 9291 - 9300 of 10000 in total
  1. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    It is approved for use in Japan.

  2. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Synonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  3. Drug

    Utomilumab

    go.drugbank.com/drugs/DB15113
    Investigational

    Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

  4. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  5. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  6. Drug

    WU-NK-101

    go.drugbank.com/drugs/DB18350
    Investigational

    WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product

  7. Drug

    PRG-A01

    go.drugbank.com/drugs/DB18613
    Investigational

    PRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.

  8. Drug

    BGB-DXP593

    go.drugbank.com/drugs/DB16357
    Investigational

    [L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants

  9. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. … Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.

    Synonyms: E 7090
  10. Drug

    PF-03882845

    go.drugbank.com/drugs/DB11814
    Investigational

    PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.